Related Experiment Video
Updated: Aug 25, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Insights
Cleveland Clinic doubled tissue plasminogen activator use, significantly reducing brain bleeding complications. This achievement earned them the 2003 Ernest A. Codman Award for excellence in healthcare.
Area of Science:
- Neurology
- Cardiology
- Medical Quality Improvement
Background:
- Intravenous tissue plasminogen activator (tPA) is a critical treatment for acute ischemic stroke.
- Hemorrhagic complications are a significant concern with tPA therapy.
Purpose of the Study:
- To evaluate the impact of increased tPA utilization on patient outcomes.
- To assess the reduction in post-treatment brain hemorrhage frequency.
Main Methods:
- Analysis of treatment protocols and outcomes within the Cleveland Clinic Health System.
- Comparative assessment of tPA usage rates and complication frequencies before and after protocol changes.
Main Results:
- Achieved a twofold increase in the administration of intravenous tPA.
- Reduced the incidence of brain hemorrhagic complications by over 50%.
Conclusions:
- Optimized tPA administration protocols can enhance treatment efficacy.
- Effective management strategies can significantly mitigate the risks associated with tPA therapy.
Abstract:
Doubling the use of intravenous tissue plasminogen activator and reducing the frequency of brain hemorrhagic complications by more than half has earned the Cleveland Clinic Health System the Ernest A. Codman Award for 2003.
Related Concept Videos
Imaging Studies for Cardiovascular System V: CT
Venous Thrombosis III: Interprofessional Care
Cardiac Catheterization IV: Nursing Management

